Dhansa Labs
Dhansa Labs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
2 of 4 strong
The short version
Dhansa Labs expects a revenue growth of about 20% for the current financial year. Revenue from operations increased by 10.82% YoY to Rs.
From Dhansa Labs's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Dhansa Labs expects a revenue growth of about 20% for the current financial year.
- The Atrazine project is expected to add Rs. 120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. 40 crores expected in the starting year.
- The company’s current capacity utilization is about 71%, projected to remain between 70-75% this year, prompting planned capacity expansions.
- Expansion includes a Brownfield expansion costing around Rs. 30 crores at the existing lab facility.
2 more points from Dhansa Labs's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Dhansa Labs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CBG Project: Rs. 120 crores CAPEX for a 15 TPD Compressed Biogas plant near Bundi, Rajasthan, with financial closure secured; commercial operations expected by July 2027.
- BioFuel Project: Planned next after CBG, additional to the 17 acres (total 22 acres land in Bundi) with investment around Rs. 120 crores.
- Atrazine Expansion: Rs. 30 crores investment for capacity expansion expected to start by August 2026 and stabilized by year-end, targeting Rs. 120-140 crores additional revenue annually.
- Laboratory Brownfield Expansion: Approx. Rs. 30 crores CAPEX on existing 5-acre facility, funded by minimal debt (Rs. 8-10 crores) and accruals/equity.
2 more points from Dhansa Labs's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dhansa Labs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Dhansa Labs Limited.
- However, it is noted that the company has secured long-term sales contracts for their 15 TPD Compressed Biogas (CBG) project, with commitments spanning 8 to 10 years.
- The Atrazine project is expected to start contributing revenue from August 2026, with an initial target of Rs. 40 crores in the first year and full revenue of Rs. 120-140 crores thereafter.
2 more points from Dhansa Labs's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Fertilizers & Agrochemicals this season
- Advance Agrolife Ltd (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
- Bhagiradha Chemicals & Industries Ltd (Q4 FY26)
158.1 crores . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Indogulf Cropsciences Ltd (Q4 FY26)
Successful single order in Venezuela contributing approximately INR 4 crores in revenue, indicating active export orders. Key concall takeaways from Indogulf…
- Punjab Chemicals & Crop Protection Ltd (Q4 FY26)
Overall volume growth in FY '26 was around 14%, primarily driven by new products. Key concall takeaways from Punjab Chemicals & Crop Protection Ltd's Q4 FY26…
Arthneeti Pro · Annual
Dhansa Labs and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dhansa Labs Q4 FY26 results?
Dhansa Labs expects a revenue growth of about 20% for the current financial year. Revenue from operations increased by 10.82% YoY to Rs.
What is Dhansa Labs share price analysis?
Dhansa Labs currently shows a below-average growth signal. The stock trades at a P/E of 12.2 with a market cap of ₹67 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dhansa Labs planning capital expenditure?
CBG Project: Rs.
Keep Dhansa Labs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.